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Abstract
Potassium 2-{[(2Z)-(3-hydroxy-1-methyl 2-butenylidene)]amino}-4-methyl-pentanoate (L1HK) and
potassium 2-{[(E)-1-(2-hydroxyphenyl)alkylidene]amino}-4-methyl-pentanoates (L2HK-L3HK)
underwent reactions with PhnSnCl4-n (n = 2 and 3) to give the amino acetate functionalized Schiff base
organotin(IV) complexes [Ph3SnLH]n (1-3) and [Ph2SnL] (4), respectively. These complexes have
been characterized by 1H, 13C, 119Sn NMR, IR spectroscopic techniques in combination with
elemental analyses. The crystal structures of 1 and 3 were determined. The crystal structures reveal that
the complexes exist as polymeric chains in which the L-bridged Sn-atoms adopt a trans-R3SnO2
trigonal bipyramidal configuration with the Ph groups in the equatorial positions and the axial locations
occupied by a carboxylate oxygen atom from one carboxylate ligand and the alcoholic or phenolic
oxygen atom of the next carboxylate ligand in the chain. The carboxylate ligands coordinate in the
zwitterionic form with the alcoholic/phenolic proton moved to the nearby nitrogen atom. The solution
structures were predicted by 119Sn NMR spectroscopy. When these organotin(IV) complexes were
tested against A498, EVSA-T, H226, IGROV, M19 MEL, MCF7 and WIDR human tumor cell lines,
the average ID50 values obtained were 55, 80 and 35 ng/ml for triphenyltin(IV) compounds 1-3,
respectively. The most cytotoxic triphenyltin(IV) compound in the present report (3) with an average
ID50 value of around 35 ng/ml is found to be morer cytotoxic for all the cell lines studied than
doxorubicin, cisplatin, 5-fluorouracil and etoposide.
 1 
Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: 
synthesis, structural characterization and in vitro cytotoxicity studies 
 
Tushar S. Basu Baul a,*, Smita Basu a, Dick de Vos b, Anthony Linden c,* 
 
aDepartment of Chemistry, North-Eastern Hill University, NEHU Permanent Campus, 
Umshing, Shillong 793022, India 
             bPharmachemie BV, P.O. Box 552, 2003 RN Haarlem, The Netherlands 
cInstitute of Organic Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 
Zurich, Switzerland 
 
Summary Potassium 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-4-methyl-pentanoate 
(L1HK) and potassium 2-{[(E)-1-(2-hydroxyphenyl)alkylidene]amino}-4-methyl-pentanoates (L2HK-
L3HK) underwent reactions with PhnSnCl4-n (n = 2 and 3) to give the amino acetate functionalized 
Schiff base organotin(IV) complexes [Ph3SnLH]n (1-3) and [Ph2SnL] (4), respectively. These 
complexes have been characterized by 1H, 13C, 119Sn NMR, IR spectroscopic techniques in 
combination with elemental analyses. The crystal structures of 1 and 3 were determined. The crystal 
structures reveal that the complexes exist as polymeric chains in which the L-bridged Sn-atoms adopt 
a trans-R3SnO2 trigonal bipyramidal configuration with the Ph groups in the equatorial positions and 
the axial locations occupied by a carboxylate oxygen atom from one carboxylate ligand and the 
alcoholic or phenolic oxygen atom of the next carboxylate ligand in the chain. The carboxylate 
ligands coordinate in the zwitterionic form with the alcoholic/phenolic proton moved to the nearby 
nitrogen atom. The solution structures were predicted by 119Sn NMR spectroscopy. When these 
organotin(IV) complexes were tested against A498, EVSA-T, H226, IGROV, M19 MEL, MCF7 and 
WIDR human tumor cell lines, the average ID50 values obtained were 55, 80 and 35 ng/ml for 
triphenyltin(IV) compounds 1-3, respectively. The most cytotoxic triphenyltin(IV) compound in the 
present report (3) with an average ID50 value of around 35 ng/ml is found to be morer cytotoxic for all 
the cell lines studied than doxorubicin, cisplatin, 5-fluorouracil and etoposide.  
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Introduction 
 
One of the most important goals of pharmacological research is the search for new molecular 
structures which exhibit effective antitumour activities [1-2]. This has driven inorganic and 
organometallic chemists to look for new metal compounds with good activities, preferably against 
tumours that are responsible for high cancer mortality. Organotin(IV) compounds are a widely 
studied class of metal-based antitumour drugs and their intensive investigation has led to the 
discovery of compounds with excellent in vitro antitumour activity, but, in many cases, 
disappointingly low in vivo potency or high in vivo toxicity [3-5]. It is well established that 
organotin(IV) compounds are very important in cancer chemotherapy because of their apoptotic 
inducing character [6,7]. The design of improved organotin(IV) antitumour agents occupies a 
significant place in cancer chemotherapy, as revealed from their remarkable therapeutic potential 
reflected in recent research reports [8-19]. 
The binding ability of organotin(IV) compounds towards DNA depends on the coordination 
number and nature of the groups bonded to the central tin atom. The phosphate group of DNA 
sugar backbones usually acts as an anchoring site and the nitrogen of DNA base binding is 
extremely effective, this often resulting in the stabilization of the tin center as an octahedral species. 
Low doses of organotins can exhibit anti-tumoural activity [20-25] and have suggested an action 
mode via gene-mediated pathway in the cancer cells, opening a new research sub-area on 
organotin(IV) compounds. The chemical and biochemical aspect of DNA inhibition, including 
biotechnological aspects of organotin(IV) cancer chemotherapy, has also been described [26]. 
Organotin(IV) halides and their complexes with amines and other ligands exhibit borderline 
activities in vivo against P388 and L1210 leukaemia. The in vivo pre-screenings against these two 
cancers used initially by the National Cancer Institute (NCI), USA, were later replaced by in vitro 
pre-screenings against a panel of human tumour cell lines, viz., MCF-7 and EVSA-T ( mammary 
cancers), WIDR (colon cancer), IGROV (ovarian cancer), M19 MEL (melanoma), A498 (renal 
cancer) and H226 (non-small-cell lung cancer) [27].  
When organotin(IV) halides are dissolved in water, the pH of the solution decreases 
dramatically because they are converted slowly into organotin(IV) hydroxides and then to 
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bis(triorganotin)oxides or diorganotin oxides. In contrast, di- and tri-organotin(IV) carboxylates do 
not suffer from this disadvantage and generally remain intact in water for long periods; i.e. days. 
Consequently, a large number of organotin(IV) carboxylates have been investigated for their 
antitumour potential. Among organotin(IV) carboxylates, triorganotin(IV) carboxylates are quite 
well known as bactericides and fungicides [28,29] and subsequently several such derivatives were 
found to be potent when screened for their cytotoxicity [30-32]. Exceptionally high in vitro 
antitumour activities were also reported for triphenyltin(IV) benzoates and salicylates against a 
human mammary tumour (MCF-7) and a colon carcinoma (WIDR) and found to comparable with 
that of mitomycin C [33]. Several attempts were also made to synthesize triphenyltin(IV) 
carboxylates by modifying the carboxylate moiety with biologically active carboxylate moieties and 
also by incorporating lipophilic/hydrophilic properties in them, since the lipophilic properties are 
essential for crossing the cell membrane and their hydrophilic character for being accepted by the 
water-rich cell [27]. The promising development in the search for antitumour organotin(IV) 
compounds has been achieved with some triphenyltin(IV) carboxylates, such as 3,6-
dioxaheptanoate and 3,6,9-trioxadecanoate [34], 4-carboxybenzo-15-crown-5 and 4-carboxybenzo-
18-crown-6 [34-35], steroidcarboxylate [36] and terebate [27,32,37] when screened in vitro against 
human tumour cell lines, as per the NCI protocol. 
 In view of the increasing interest in organotin(IV) carboxylates and prompted by their 
structural diversity [38] and broad therapeutic activity [27], organotin(IV) complexes of Schiff 
bases derived from amino acids have also been investigated extensively [39-49]. An overview of 
the coordination behaviour of such Schiff bases towards organotin(IV) is shown in Scheme 1. Some 
of these organotin(IV) compounds were screened for antitumour activity in vivo in Ehrlich ascites 
carcinoma cells [41] and cytotoxic activity in vitro against cell lines of human origin [47,49]. The 
in vitro cytotoxicity results demonstrated that triphenyltin(IV) compounds derived from 2-{[(2Z)-
(3-hydroxy-1-methyl-2-butenylidene)]amino}-, 2-{[(E)-1-(2-hydroxyphenyl)methylidene]amino}- 
and 2-{[(E)-1-(2-hydroxyphenyl)ethylidene]amino}-phenylpropionates are more active than CDDP 
(cisplatin) [49]. Interestingly, all three triphenyltin(IV) compounds show comparable cytotoxic 
activity across a panel of cell lines and this prompted us to investigate related systems by modifying 
the amino acetate part of the molecule, which might improve dissolution properties and thereby 
influence cytotoxicity. Within this paper, we present a series of new organotin(IV) carboxylates 
involving the 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-4-methyl-pentanoate and 2-
{[(E)-1-(2-hydroxyphenyl)-alkylidene]amino}-4-methyl-pentanoate skeletons (Scheme 2, 
compounds 1-4), their synthesis, spectroscopic characterization, crystal structures and preliminary 
cytotoxic studies.   
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Scheme 1 An overview showing the coordination behaviour of Schiff bases with amino acids 
towards the organotin(IV) moiety.  
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Experimental 
    
   Materials 
Ph3SnCl (Fluka AG), Ph2SnCl2, 2’-hydroxyacetophenone (Aldrich), l-leucine (Himedia), 2-
hydroxybenzaldehyde and acetylacetone (Sisco) were used without further purification. The 
solvents used in the reactions were of AR grade and were dried using standard procedures.  
 
Physical measurements 
 
Carbon, hydrogen and nitrogen analyses were performed with a Perkin Elmer 2400 series II 
instrument. IR spectra in the range 4000-400 cm-1 were obtained on a Perkin Elmer Spectrum BX 
series FT-IR spectrophotometer with samples investigated as KBr discs. The 1H-, 13C- and 119Sn-
NMR spectra were recorded on a Bruker AMX 400 spectrometer and measured at 400.13, 100.62 
and 149.18 MHz. The 1H, 13C and 119Sn chemical shifts were referred to Me4Si set at 0.00 ppm, 
CDCl3 set at 77.0 ppm and Me4Sn set at 0.00 ppm, respectively.  
 
X-ray crystallography 
 
Crystals of compounds 1 and 3 suitable for an X-ray crystal-structure determination were obtained 
from toluene/hexane (v/v 1:1) and ethanol, respectively, by slow evaporation of the solutions of the 
respective compounds. All measurements were made on a Nonius KappaCCD diffractometer [50] 
with graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) and an Oxford Cryosystems 
Cryostream 700 cooler. Data reduction was performed with HKL Denzo and Scalepack [51]. The 
intensities were corrected for Lorentz and polarization effects, and empirical absorption corrections 
based on the multi-scan method [52] were applied. Equivalent reflections, other than Friedel pairs, 
were merged. The data collection and refinement parameters are given in Table 1, and views of the 
molecules are shown in Figs. 1 and 2. The structure of 1 was solved by direct methods using SIR92 
[53].  Heavy-atom Patterson methods [54] were employed for 3, which revealed the position of the 
Sn-atom, and the remaining non-hydrogen atoms in 3 were located in a Fourier expansion of the 
Patterson solution, which was performed by DIRDIF94 [55].   
 Both triphenyltin(IV) compounds exist as polymeric chains with the carboxylate ligands 
bridging between the Sn-atoms and in each case the asymmetric unit contains just one of the 
chemical repeat units of the polymer.  One of the phenyl ligands in 1 and 3 and the iso-propyl group 
in 1 are disordered over two orientations. Two sets of overlapping positions were defined for the 
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atoms of the disordered groups and the site occupation factors of the major conformations of these 
groups refined to 0.578(9), 0.552(8) and 0.70(1), respectively.  Similarity restraints were applied to 
the chemically equivalent bond lengths and angles involving all disordered C-atoms, while 
neighbouring atoms within and between each conformation of the disordered groups were 
restrained to have similar atomic displacement parameters.   
 The imine H-atom in 1 was placed in the position indicated by a difference electron density 
map and its position was allowed to refine together with an isotropic displacement parameter. All 
remaining H-atoms were placed in geometrically calculated positions and refined by using a riding 
model where each H-atom was assigned a fixed isotropic displacement parameter with a value 
equal to 1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups). The refinement of each 
structure was carried out on F2 by using full-matrix least-squares procedures, which minimized the 
function Σw(Fo2 – Fc2) 2.  Corrections for secondary extinction were applied. Two reflections in 3, 
whose intensities were considered to be extreme outliers, were omitted from the final refinement. 
Refinement of the absolute structure parameter [56] for 1 and 3 yielded the values of -0.02(2) and -
0.05(3), respectively, which confidently confirm that the refined coordinates represent the true 
enantiomorph. All calculations were performed using the SHELXL97 program [57]. 
 Several crystals of 2 were tried, but all seem to exhibit diffuse scattering.  Although the overall 
structure could be discerned and is very similar to that of 3, the R-factors remained very high, the 
refinement is unstable because of pseudosymmetry, and there is some unresolvable disorder at the 
chrial centre of the l-leucine ligand. For these reasons, the details of this structure are not reported 
here. Visual inspection of the crystals showed that they tended to grow in layered blocks.  An 
individual layer could be isolated by careful cutting, but this did not yield improved data.  It is 
possible that twinning has occurred, although twin analysis software did not reveal any twin laws 
and reconstructed precession images were also reasonably clean.  Data collection at various 
temperatures did not improve the results. 
 
Synthesis 
 
Synthesis of the potassium salts 
 
A typical procedure is described below.  
Potassium 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-4-methyl-pentanoate (L1HK) 
was prepared by slow addition of a methanol solution (2 ml) of KOH (0.19 g, 3.38 mmol) to l-
leucine (0.44 g, 3.35 mmol) in 10 ml methanol with continuous stirring. A methanolic solution (15 
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ml) of acetylacetone (0.33 g, 3.29 mmol) was added drop-wise. A pale yellow colour developed 
almost immediately and stirring was continued for 1 h, followed by 5 h refluxing. The volatiles 
were removed carefully; the pale yellow mass was stirred with diethylether and filtered. The residue  
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Scheme 2 Syntheses of potassium salts (L1HK-L3HK) along with the numbering scheme and their 
triphenyltin(IV) complexes (1-3). The structure of diphenyltin(IV) complex (4) is included for the 
convenience of discussion.   
 
was dissolved in the minimum amount of anhydrous methanol and filtered. The filtrate was 
precipitated with diethylether which afforded the crude product. Repeated precipitations from a 
methanol-diethylether mixture yielded pure L1HK, which was then dried in vacuo (0.68 g, 81% 
yield). M.p.: 70-72 °C. Anal. Calc. for C11H18NKO3:  Theory: C, 52.56; H 7.21; N; 5.57%. Found: 
C, 52.50; H, 7.16; N, 5.52%. IR absorptions (cm-1): 1672 ν(OCO)asym, 1606  ν(C=N), 1301 ν(Ph(C-
O)). 
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The other potassium salts (Scheme 2), viz., potassium 2-{[(E)-1-(2-
hydroxyphenyl)methylidene]amino}-4-methyl-pentanoate (L2HK) and potassium 2-{[(E)-1-(2-
hydroxyphenyl)ethylidene]amino}-4-methyl-pentanoate (L3HK) were prepared analogously by 
reacting 2-hydroxybenzaldehyde and 2’-hydroxyacetophenone, respectively, with potassium l-
leucinate. L2HK: Recrystallized from methanol to give a bright yellow precipitate in 83.7% yield. 
M.p.: 153-55 °C. Anal. Calc. for C13H16NKO3: Theory: C, 57.11; H, 5.90; N, 5.12%. Found: C, 
57.03; H, 5.88; N, 5.10%. IR absorptions (cm-1): 1639 ν(OCO)asym, 1613 ν(C=N), 1374 ν(Ph(C-O)). 
L3HK: Recrystallized from methanol to give a yellow precipitate in 78.7% yield. M.p.: 145-47 ºC 
(decomp.). Anal. Calc. for C14H18NKO3:  Theory: C, 58.51; H, 6.31; N, 4.87%. Found: C, 58.40; H, 
6.20; N, 5.04%. No meaningful IR spectrum could be recorded owing to fast decomposition of the 
sample. 
 
Synthesis of the organotin(IV) complexes 
 
Synthesis of [Ph3SnL1H]n (1)   
            Ph3SnCl (0.55g, 1.43 mmol) in anhydrous methanol (ca. 10 ml) was added drop-wise to a 
stirred anhydrous methanol solution (ca. 20 ml) containing L1HK (0.36g, 1.43 mmol). The solution 
was refluxed for 5 h at ambient temperature and the volatiles were removed in vacuo. The residue 
was washed thoroughly with hexane, filtered and dried in vacuo. The residue was extracted into 
anhydrous benzene and filtered. The benzene solution was concentrated to a minimum and 
precipitated with hexane. The precipitate was washed several times with hexane, dried in vacuo and 
recrystallized from toluene-hexane mixture (1:1 v/v) to yield colourless crystals of 1 in 83.5% 
(0.66g) yield. M.p.: 135-137 °C. Anal. Calc. for C29H33NO3Sn:  Theory: C, 61.95; H, 5.92; N, 
2.49%. Found: C, 61.90; H, 5.85; N, 2.40%. IR absorptions (cm-1): 1646 ν(OCO)asym, 1600 ν(C=N),  
1261  ν(Ph(CO)). 1H-NMR (CDCl3): Ligand skeleton: 10.92 (brs, 1H, OH), 4.97 (s, 1H, H-4), 4.18 
(d (7.7 Hz); 3J(119/117Sn-1H = 22 Hz)), 1H, H-2),  2.01 (s, 2H, H-6), 1.74 (s, 6H, H-3’and H-5’), 1.59 
(s, 1H, H-7), 0.91 and 0.85 (d (7 Hz), 6H, H-8a and H-8b); Sn-Ph skeleton: 7.78 (m, 6H, H-2*), 
7.45 (m, 9H, H-3* and H-4*), ppm. 13C-NMR (CDCl3): Ligand skeleton: 195.4 (C-1), 177.9 (C-5), 
162.3 (C-3), 96.3 (C-4), 55.1 (C-2), 41.9 (C-6), 28.9 (C-7), 24.8 and 18.9 (C-3’ and C-5’), 22.9 and 
21.8 (C-8a and C-8b);  Sn-Ph skeleton (nJ(13C-119/117Sn, Hz)): 137.9 (662/634) (C-1*), 136.9 (48) 
(C-2*), 130.3 (14) (C-4*), 129.0 (64) (C-3*), ppm. 119Sn-NMR (CDCl3): -103.7 ppm.   
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Synthesis of [Ph3SnL2H]n (2)   
An identical method to that used for the preparation of 1 was followed using Ph3SnCl and 
L2HK. Yellow crystals of compound 2 were obtained from ethanol in 79% yield. M.p.: 153-55 °C. 
Anal. Calc. for C31H31NO3Sn: Theory: C, 63.73; H, 5.35; N, 2.40%. Found: C, 63.65; H, 5.30; N, 
2.45 %. IR absorptions (cm-1): 1646 ν(OCO)asym, 1546 ν(C=N),  1288 ν(Ph(CO)). 1H-NMR 
(CDCl3): Ligand skeleton: 13.3 (brs, 1H, OH), 8.32 (s, 1H, H-3’), 7.31 (t, 1H, H-7), 7.20 (d, 1H, H-
9), 6.97 (d, 1H, H-6), 6.86 (t, 1H, H-8), 4.16 (d (3.3 Hz); 3J(119/117Sn-1H = 14 Hz)), 1H, H-2), 1.88 
(s, 2H, H-10), 1.58 (s, 1H, H-11), 0.90 and 0.86 (d (7 Hz), 6H, H-12a and H-12b); Sn-Ph skeleton: 
7.71 (m, 6H, H-2*), 7.45 (m, 9H, H-3* and H-4*), ppm.  13C-NMR (CDCl3): Ligand skeleton: 
177.6 (C-1), 165.8 (C-5), 161.4 (C-3), 132.5 (C-7), 131.6 (C-9), 118.8 (C-4), 118.5 (C-8), 117.2 (C-
6), 69.7 (C-2), 42.9 (C-10), 24.7 (C-11), 23.1 and 21.6 (C-12a and C-12b); Sn-Ph skeleton (nJ(13C-
119/117Sn, Hz)): 137.9 (654/627) (C-1*), 136.9 (48) (C-2*), 130.3 (16) (C-4*), 129.0 (63) (C-3*), 
ppm. 119Sn-NMR (CDCl3): -100.2 ppm.   
 
Synthesis of [Ph3SnL3]n (3)   
           A mixture of Ph3SnCl (0.80g, 2.07 mmol) and L3HK (0.60g, 2.08 mmol) were refluxed in 
benzene (35 ml) for 6 h. The bright yellow solution was filtered and the filtrate was evaporated to a 
minimum and precipitated with hexane to give the crude product. The precipitate was filtered, dried 
in vacuo and upon recrystallization from ethanol furnished light fluorescent yellow crystals of 3 in 
86% (1.07 g) yield. M.p.: 158-60 °C. Anal. Calc. for C32H33NO3Sn: Theory: C, 64.24; H, 5.56; N, 
2.34%. Found: C, 63.89; H, 5.46; N, 2.21%. IR absorptions (cm-1): 1653 ν(OCO)asym, 1613 ν(C=N),  
1261 ν(Ph(CO)). 1H-NMR (CDCl3): Ligand skeleton: 16.1 (brs, 1H, OH), 7.41 (m (overlapped with 
Sn-Ph H-3* and H-4*), 1H, H-9), 7.31 (t, 1H, H-7), 6.97 (d, 1H, H-6), 6.78 (t, 1H, H-8), 4.53 (d 
(3.3 Hz); 3J(119/117Sn-1H = 14 Hz)), 1H, H-2), 2.64 (s, 2H, H-10), 2.22 (s, 1H, H-3’), 1.93 (s, 1H, H-
11), 0.92 and 0.85 (d (7 Hz), 6H, H-12a and H-12b); Sn-Ph skeleton: 7.65 (m, 6H, H-2*), 7.41 (m, 
9H, H-3* and H-4*), ppm. 13C-NMR (CDCl3): Ligand skeleton: 177.5 (C-1), 172.3 (C-5), 163.8 (C-
3), 132.6 (C-7), 128.3 (C-9), 118.9 (C-4), 118.8 (C-8), 117.1 (C-6), 60.8 (C-2), 43.1 (C-10), 25.0 
(C-11), 23.0 and 21.9 (C-12a and C-12b), 14.9 (C-3’); Sn-Ph skeleton (nJ(13C-119/117Sn, Hz)): 137.9 
(654/627) (C-1*), 136.7 (50) (C-2*), 129.9 (16) (C-4*), 128.8 (64) (C-3*), ppm. 119Sn-NMR 
(CDCl3): -83.1 ppm.   
 
Synthesis of [Ph2SnL2H]n (4)   
Ph2SnCl2 (0.50 g, 1.42 mmol) in hot anhydrous benzene (45 ml) was added drop-wise to 
L2HK (0.39 g, 1.42 mmol) suspended in anhydrous benzene (30 ml) with continuous stirring. The 
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reaction mixture was refluxed for 1h, then triethylamine (0.15 ml, 1.42 mmol) was added and 
refluxing was continued for additional 5 h.  The reaction mixture was cooled to room temperature 
and filtered to remove Et3N.HCl. The filtrate was collected; volatiles were removed in vacuo. The 
dried residue was washed thoroughly with hexane and then extracted into warm benzene (25 ml) 
and filtered. The filtrate was concentrated, precipitated with hexane, filtered and the light yellow 
residue obtained was dried in vacuo. The crude product was then re-crystallized from ethanol which 
afforded a lemon yellow microcrystalline product of 4 in 76.7% (0.69 g) yield. M.p.: 191-193 °C 
(207-208 °C [58]). Anal. Calc. for C25H25NO3Sn: Theory: C, 59.32; H, 4.98; N, 2.77. Found: C, 
59.29; H, 4.90; N, 2.84 %.  IR absorptions (cm-1): 1686 ν(OCO)asym, 1619 ν(C=N),  1321 
ν(Ph(CO)). 1H-NMR (CDCl3): Ligand skeleton: 8.22 (s, (3J(119/117Sn-1H = 57 Hz)), 1H, H-3’), 7.55 
(t, 1H, H-7), 7.19 (d, 1H, H-9), 7.15 (d, 1H, H-6), 6.81 (t, 1H, H-8), 4.17 (d (3.0 Hz); (3J(119/117Sn-
1H = 14 Hz)), 1H, H-2), 1.81 and 1.52 (m, 2H, H-10), 1.63 (m, 1H, H-11), 0.90 and 0.81 (d (7 Hz), 
6H, H-12a and H-12b); Sn-Ph skeleton: 7.98 and 7.82 (m, 4H, H-2*), 7.47 and 7.36 (m, 6H, H-3* 
and H-4*), ppm. 13C-NMR (CDCl3): Ligand skeleton: 173.7 (C-1), 171.6 (C-5), 169.2 (C-3), 138.0 
(C-7), , 135.5 (C-9), 122.8 (C-8), 117.8 (C-6), 117.1 (C-4), 67.6 (C-2), 44.7 (C-10), 23.7 (C-11), 
22.7 and 21.8 (C-12a and C-12b); Sn-Ph skeleton (nJ(13C-119/117Sn, Hz)): 137.5 (994) and 137.4 
(962) (C-1*), 136.5 (57) and 136.2 (57) (C-2*), 130.7 (98) and 130.6 (78) (C-4*), 128.8 (17) and 
128.7 (17) (C-3*), ppm. 119Sn-NMR (CDCl3): -340.5 ppm.   
 
Experimental protocol and cytotoxicity tests  
 
The experiment was started on day 0. On day 0, 10000 cells per well were seeded into 96-wells flat-
bottomed micro-titer plates (falcon 3072, DB). The plates were pre-incubated overnight at 37 °C, 5 
% CO2 to allow the cells to adhere to the bottom. On day 1, a three-fold dilution sequence of ten 
steps was made in full medium, starting with the 250 000 ng/ml stock solution. Every dilution was 
used in quadruplicate by adding 200 µl to a column of four wells. This procedure results in the 
highest concentration of 625000 ng/ml being present in column 12. Column 2 was used for the 
blank. After incubation of 3 days, the plates were washed with PBS twice. Fluorescein diacetate 
(FDA) stock solution was diluted to 2 µg/ml with PBS and 200 µl of this solution was added to each 
of the control, experimental and blank wells. The plates were incubated for 30 min at 37 °C and the 
fluorescence generated from each well was measured at an excitation wavelength of 485 nm and an 
emission wavelength of 535 nm using an automated microplate reader (Labsystems Multiskan MS). 
The data were used for construction of concentration-response curves and determination of the ID50 
values by use of Deltasoft 3 software. 
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The variability of the in vitro cytotocicity test depends on the cell lines used and the serum 
applied. With the same batch of cell lines and the same batch of serum the inter-experimental CV 
(coefficient of variation) is 1-11% depending on the cell line and the intra-experimental CV is 2-
4%. These values may be higher with other batches of cell lines and/or serum. 
 
Results and discussion 
 
Synthesis and Spectroscopy  
Potassium salts L1HK- L3HK were prepared by reacting acetylacetone, 2-hydroxybenzaldehyde or 
2’-hydroxyacetophenone with potassium l-leucinate in methanol. Triphenyltin(IV) compounds viz., 
[Ph3SnL1H]n (1), [Ph3SnL2H]n (2) and  [Ph3SnL3H]n (3) could easily be prepared by reacting 
potassium salts with Ph3SnCl either in refluxing methanol or benzene in greater than 76% yields. 
On the other hand, [Ph2SnL2H]n (4)  was prepared by reacting the appropriate potassium salt with 
Ph2SnCl2 in benzene in the presence of Et3N as a proton abstractor, a method similar to that 
reported earlier [59]. The synthesis of these compounds is shown in Scheme 2. The compounds are 
shiny colourless to yellow solids. They are stable in air and soluble in all common organic solvents. 
 The IR spectra displayed a strong sharp band at around 1650 cm-1 for triphenyltin(IV) 
complexes (1-3) and at around 1685 cm-1 for diphenyltin(IV) complex (4) which has been assigned 
to the carboxylate antisymmetric [νasym(OCO)] stretching vibration, in accord with our earlier 
reports [39,42,43,47,49]. The assignment of the symmetric [νsym(OCO)] stretching vibration band 
could not be made owing to the complex pattern of the spectra. The 1H- and 13C- NMR signals were 
assigned by the use of homonuclear correlated spectroscopy (COSY), heteronuclear single-quantum 
correlation (HSQC), heteronuclear multiple-bond connectivities (HMBC) and distortionless 
enhancement by polarization transfer (DEPT) experiments. The 1H and 13C chemical shift 
assignment (see Experimental) of the phenyltin moiety is straightforward from the multiplicity 
patterns, resonance intensities and also by comparing their nJ(13C-119/117Sn) values. The 1H-NMR 
integration values were completely consistent with the formulation of the products. The 13C-NMR 
spectra of the ligand and Sn-Ph skeletons displayed the expected carbon signals in triphenyltin(IV) 
complexes 1-3. The diphenyltin(IV) complex (4) deserves specific mention. The spin-spin coupling 
of 57 Hz between the azomethine proton and the tin nucleus, 3J(119/117SnN=C1H) has been detected. 
Such coupling has previously been reported for the complexes where tin nuclei are located in a 
trans- position to the azomethine proton [60], confirming the presence of nitrogen-tin coordination. 
In addition, complex 4 (Ph2Sn(2-OC6H4C(H)=NCHCH2CH(CH3)2COO) displayed two sets of 1H 
and 13C NMR signals from the Sn-Ph groups (see experimental) since the italicised proton in the 
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complex is enantiotropic and causes the phenyl groups bound to the tin, and the iBu group to be 
diastereotopic [61], and thereby the two phenyl groups (Sn-Ph2) experience different environments 
on the NMR time scale. These observations were noted earlier for diorganotin(IV) complexes of 2-
{[(E)-1-(2-oxyphenyl)alkylidene]amino}phenylpropionate [49]. The triphenyltin(IV) complexes (1-
3) in CDCl3 exhibit a single sharp 119Sn resonance in the range -83 to -103 ppm, suggesting that the 
Sn-atoms in the complexes have the same four-coordinate environment [42,47,49,62,63]. This is 
also reflected in 1J(13C-119/117Sn) coupling constants (see experimental) and the values are 
unambiguously characteristic for four-coordinate tin atoms [63]. These results demonstrate that the 
polymeric structure with five-coordinate tin atoms found in the solid state is lost upon dissolution 
(see below for the crystal structure discussion). On the other hand, the X-ray crystal structure of 
complex 4 demonstrated a pseudo-trigonal bipyramid geometry around tin atom [58]. The chemical 
shift data for this complex in CDCl3 displayed a 119Sn chemical shift at -340 ppm, which closely 
matches the shifts reported for diphenyltin(IV) amino acetate [39,41], which has five-coordinate 
Sn-atoms in solution. This shift testifies that the solid structure of 4, revealed in the crystal 
structure, is retained in solution.  
 
Crystal structures 
 The crystal structures of compounds 1 and 3 reveal that the Sn-coordination complex in each 
case has the basic type X polymeric chain structural motif described in Scheme 1. A preliminary 
investigation of the crystal structure of 2 revealed the same motif, but this structure is not described 
in any further detail here (see the Experimental details).  Views of the molecular structures of 
complexes 1 and 3 are shown in Figs. 1 and 2 (refer to Scheme 2 for line diagrams), while selected 
geometric parameters are collected in Table 2.  
 The following specific details are given for the structure of 1, but the comments apply equally 
well to the structures of 2 and 3. It is apparent that varying the organic moiety in the Schiff base 
ligands has an insignificant influence on the overall structure and the coordination geometry of the 
Sn-atoms. Complex 1 has a polymeric chain structure in which a single carboxylate ligand bridges 
adjacent Sn-centres via its carboxylate and oxide O-atoms. The asymmetric unit contains one of the 
chemical repeat units of the polymeric Sn-compound. Compounds 1 and 3 in the crystal are 
enantiomerically pure and the absolute configuration of the molecules has been determined 
independently by the diffraction experiments. The stereogenic centre at C(2) of the molecules 1 and 
3 has the S-configuration expected of l-leucine. 
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The primary coordination sphere of the Sn-atom is trigonal bipyramidal with the phenyl 
ligands in the equatorial plane and the axial positions occupied by one O-atom from the carboxylate 
group of one carboxylate ligand and the oxide O-atom of the next carboxylate ligand in the chain.  
This yields a trans-R3SnO2 geometry.  The second O-atom of the carboxylate group is not involved 
in the primary coordination sphere of the Sn-atom, but lies 3.386(3) Å (3.537(5) Å in 3) from the 
Sn-atom. Polymeric chain structures involving triphenyltin(IV) and the Schiff bases of amino acids 
with a similar mode of coordination and geometry about the Sn-atom have been observed in 
triphenyltin 2-{[(E)-1-(2-hydroxyphenyl)methylidene]amino}acetate [42], 2-{[(2Z)-(3-hydroxy-1-
methyl-2-butenylidene)]amino}phenylpropionate [49], 2-{[(E)-1-(2-hydroxyphenyl) 
methylidene]amino}phenylpropionate [49] and 2-{[(E)-1-(2-hydroxyphenyl)ethylidene]amino}- 
phenylpropionate [49]. Among all of these structures, the greatest variation in the coordination 
geometry is in the Sn-O(oxide) bond length, which ranges from 2.242(2) Å in 3 to 2.539(2) Å in 2-
{[(E)-1-(2-hydroxyphenyl)methylidene]amino}phenylpropionate [49].  The formal hydroxy group 
in the carboxylate ligand of 1 and 3 has lost its H-atom, so is negatively charged. Instead the imine 
N-atom is protonated, thus leading to a zwitterionic ligand. This N+–H group forms an 
intramolecular hydrogen bond with the oxide O-atom. The H-bond parameters (D-H, H···A, D···A 
and D-H···A) for the fairly strong bifurcated N-H···O H-bonds are presented in Table 3. One of the 
phenyl ligands and the iso-propyl group in 1 are disordered over two orientations while one of the 
phenyl ligands is disordered over two almost equally occupied orientations in 3. 
The polymeric structures of the triphenyltin(IV) complexes 1-3, is not repeated in the crystal 
structure of diphenyltin(IV) complex 4, as described by Wang et al. [58]. In 4, a mononuclear 
discrete molecule, the arrangement of the donor set about the Sn-atom is distorted trigonal 
bipyramidal with one carboxylate and the oxide oxygen atoms from the tridentate carboxylate 
ligand occupying the axial positions, while the imine nitrogen atom from the carboxylate ligand and 
two phenyl groups are in equatorial positions (refer to Scheme 2).  
 
Cytotoxicity studies  
 
The in vitro cytotoxicity test of organotin(IV) compounds 1-4 was performed using the SRB test for 
the estimation of cell viability. The cell lines WIDR, M19 MEL, A498, IGROV and H226 belong 
to the currently used anticancer screening panel of the NCI, USA [64]. The MCF7 cell line is 
estrogen receptor (ER)+/ progesterone receptor (PgR)+ and the cell line EVSA-T is (ER)-/(Pgr)-. 
Prior to the experiments, a mycoplasma test was carried out on all cell lines and found to be 
negative. All cell lines were maintained in a continuous logarithmic culture in RPMI 1640 medium 
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with Hepes and phenol red. The medium was supplemented with 10% FCS, penicillin 100 µg/ml 
and streptomycin 100 µg/ml. The cells were mildly trypsinized for passage and for use in the 
experiments. RPMI and FCS were obtained from Life technologies (Paisley, Scotland). SRB, 
DMSO, Penicillin and streptomycin were obtained from Sigma (St. Louis MO, USA), TCA and 
acetic acid from Baker BV (Deventer, NL) and PBS from NPBI BV (Emmer-Compascuum, NL). 
The test compounds 1-4 and reference compounds were dissolved to a concentration of 250000 
ng/ml in full medium, by 20 fold dilution of a stock solution which contained 1 mg of compounds 
1-4 / 200 µl. All the four compounds were dissolved in DMSO. Cytotoxicity was estimated by the 
microculture sulforhodamine B (SRB) test [65].  
The results of the in vitro cytotoxicity tests performed with triphenyltin(IV) compounds, (1-3) 
and diphenyltin(IV) compound (4) are summarized in Table 4 and the screening results are 
compared with the results from other related triphenyltin(IV)- and diorganotin(IV)- compounds 
with respect to the standard drugs that are in current clinical use as antitumour agents. Recently, we 
have reported in vitro cytotoxic results on triphenyltin(IV) compounds  5-7 where the ligand is a 
Schiff base derived from phenylalanine [49]. There are also reports on di-n-butyltin(IV) and 
diphenyltin(IV) compounds with Schiff bases derived from glycine, β-alanine,  and l-leucine and 
these were also investigated for in vitro cytotoxic potential (see Table 4 for details) [66]. Di-n-
butyltin(IV) compounds of cognate system were also investigated for antitumour activity against 
the NCI panel of 60 cell lines [67]. The results indicated that three of the di-n-butyltin(IV) 
compounds, viz., nBu2Sn(2-OC6H4C(H)=NCH2COO), nBu2Sn(2-OC6H4C(CH3)=NCH2COO) and 
nBu2Sn(2-OC6H4C(H)=NCHCH(CH3)2COO)  exhibited very high cytotoxic effect on the NCI-522 
(non-small cell lung cancer) cell line. The fourth compound, nBu2Sn(2-OC10H6C(H)=NCH2COO) 
exhibited highest cytotoxic activity on the cell line RXF-631L (renal cancer). In general, a low to 
moderate cellular response was observed for all the di-n-butyltin(IV) compounds, with at least one 
cell line in each subpanel of cells exhibiting a very low growth inhibition response. The results also 
indicated that the compounds did not exhibit any significant subpanel activity and suggested that 
the di-n-butyltin(IV) compounds were not active in all the cell lines contained in any subpanel. Di-
n-butyltin(IV) compound of composition  {[nBu2Sn(2-OHC6H4C(CH3)=N(CH2)2COO)]2O}2 (Table 
4) also exhibited good activity especially when compared with CCDP [47]. Another interesting 
mixed organotin(IV) binuclear compound Ph3Sn(HL).Ph2SnL (L = 2-O-3,5-
Br2C6H2C(H)=NCHCH(CH3)2COO) also displayed good in vitro cytotoxicity against three human 
tumour cell lines, i.e. HeLa (cervix tumour cell), CoLo 205 (colon carcinoma cell) and MCF-7 
(mammary tumour cell) when compared with CCDP [68,69]. 
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The triphenyltin(IV) compounds of the present investigation (1-3, Table 4) showed ID50 
values in the range 33-96, 42-104 and 31-38 ng/ml, respectively, whereas diphenyltin(IV) 
compound 4 produced an ID50 value in the range 199-987 ng/ml, across seven human tumour cell 
lines. Triphenyltin(IV) compound 3 is the most promising candidate in this study and the most 
cytotoxic organotin(IV) complex so far with a Schiff base bearing amino acetate skeleton. 
Compound 3 is around 25 fold more active in magnitude in terms of the ID50 value at least against 
the A498 and H226 cell lines and is found to be almost as cytotoxic as MTX and found to be much 
better particularly for the H226 cell line. Under identical conditions, compound 3 is far superior to 
CCDP across a panel of cell lines and the activity is more pronounced for the A498 (57 fold) and 
H226 (86 fold) cell lines. The increase in the cytotoxicity of triphenyltin(IV) compounds 1-3 across 
the cell lines is likely to be because of the non-involvement of the nitrogen atom in the 
complexation with the tin atom (see Scheme 2 and Fig. 3), which allows easy dissociation of the 
complex so that it can subsequently bind to DNA. This corroborates the fact that diorganotin(IV) 
complexes show lower activity when the nitrogen atom coordinates to the tin atom [67]. A typical 
mode of bonding of diorganotin(IV) complexes is shown in Scheme 2 taking complex 4 as an 
example. However, the variations in in vitro cytotoxicity of the triphenyltin(IV) complexes may be 
due to different kinetic and mechanistic behaviour [49]. Conversely, the possibility of organotin 
compounds to interact with DNA at the level of the phosphate groups can not be completely ruled 
out [70]. cytotoxicity In conclusion, the present study describes new structures with improved in 
vitro anti-tumour activity, which is of added value in determining the structure activity relationship 
in the area of organotin(IV) chemistry with possible future clinical application.  
 
Conclusions and outlook 
 
The manuscript reports the preparation and crystal structures of some novel triphenyltin(IV) 
complexes which may find applications in cancer chemotherapy. The most promising 
triphenyltin(IV) compound 3 shows the highest cytotoxicity so far, among the organotin(IV) 
compounds containing Schiff base amino acetate systems, when tested in vitro across seven human 
tumour cell lines indicating its high potential as an anti-cancer drug. It is intended to employ these 
compounds for testing in animal models and additionally to search for differently substituted Schiff 
base amino acetate skeletons in order to improve the solubility. Further work in this area is 
underway. 
Supplementary material 
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CCDC-696775 and CCDC-696776 contain the supplementary crystallographic data for complexes 
1 and 3, respectively. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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Table 1 Crystallographic data and structure refinement parameters for organotin(IV) 
compounds 1 and 3 
 1 3 
Empirical formula C29H33NO3Sn C32H33NO3Sn 
Formula weight 562.18 598.22 
Crystal size (mm) 0.20 × 0.25 × 0.30 0.10 × 0.12 × 0.17 
Crystal shape Prism Prism 
Temperature (K) 250(1) 160(1) 
Crystal system Orthorhombic Monoclinic 
Space group P212121  P21  
a (Å) 9.2766(1) 9.3293(2) 
b (Å) 14.0307(2) 13.6667(3) 
c (Å) 21.2691(2) 11.1178(2) 
β (°) 90 91.713(1) 
V (Å3) 2768.33(6) 1416.89(5) 
Z 4 2 
Dx (g cm-3) 1.349 1.402 
µ (mm-1) 0.950 0.933 
Transmission factors (min, max) 0.769; 0.834 0.829; 0.914 
2θmax (°) 55 55 
Reflections measured 74188 32799 
Independent reflections; Rint 6331; 0.072 6469; 0.056 
Reflections with I > 2σ(I) 5409 5819 
Number of parameters  401 393 
Number of restraints 251 170 
R(F) [I > 2σ(I)reflns] 0.036 0.046 
wR(F2) (all data) 0.084 0.114 
GOF(F2) 1.09  1.11 
Δρmax, min (e Å-3)  0.98; -0.40 1.43; -0.75 
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Table 2 Selected bond lengths (Å) and angles (°) for compounds (1 and 3)a  
1 3 
Sn(1)-O(1) 2.151(2) Sn-O(1) 2.197(4) 
Sn(1)-O(2) 3.386(3) Sn-O(2) 3.537(5) 
Sn(1)-C(11) 2.136(4) Sn-C(14) 2.124(5) 
Sn(1)-C(17) 2.132(4) Sn-C(20) 2.118(5) 
Sn(1)-C(23a) 
Sn(1)-C(23b) 
2.132(4) 
2.129(5) 
Sn-C(26a) 
Sn-C(26b) 
2.135(5) 
2.143(5) 
Sn(1)-O(3’) 2.352(2) Sn-O(3’) 2.242(4) 
    
O(1)-Sn(1)-C(11) 97.3(1) O(1)-Sn-C(14) 94.4(2) 
O(1)-Sn(1)-C(17) 95.6(1) O(1)-Sn-C(20) 92.6(2) 
O(1)-Sn(1)-C(23a) 
O(1)-Sn(1)-C(23b) 
85.3(4) 
90.7(6) 
O(1)-Sn-C(26a) 
O(1)-Sn-C(26b) 
90.5(6) 
80.4(4) 
C(11)-Sn(1)-C(17) 122.2(1) C(14)-Sn-C(20) 120.2(2) 
C(17)-Sn(1)-C(23a) 
C(17)-Sn(1)-C(23b) 
119.8(4) 
111.8(6) 
C(20)-Sn-C(26a) 
C(20)-Sn-C(26b) 
109.7(5) 
120.2(5) 
C(23a)-Sn(1)-C(11) 
C(23b)-Sn(1)-C(11) 
117.2(5) 
124.0(7) 
C(26a)-Sn-C(14) 
C(26b)-Sn-C(14) 
129.5(4) 
119.5(4) 
O(3’)-Sn(1)-C(11) 87.5(1) O(3’)-Sn-C(14) 89.1(2) 
O(3’)-Sn(1)-C(17) 87.5(1) O(3’)-Sn-C(20) 93.0(2) 
O(3’)-Sn(1)-C(23a) 
O(3’)-Sn(1)-C(23b) 
86.4(4) 
81.0(6) 
O(3’)-Sn-C(26a) 
O(3’)-Sn-C(26b) 
80.7(6) 
90.5(4) 
O(1)-Sn(1)-O(3’) 171.7(1) O(1)-Sn-O(3’) 170.8(1) 
C(1)-O(1)-Sn(1) 125.5(2) C(1)-O(1)-Sn 130.9(3) 
C(9')-O(3')-Sn(1) 134.9(2) C(13')-O(3')-Sn 130.2(3) 
a Primed atoms refer to atoms from the next symmetrically-related ligand in the polymeric 
chain (symmetry code for 1: 1-x, -1-2+y, 
1-2-z; for 3: 2-x, 
1-2+y, 1-z)  
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Table 3 Hydrogen bonding geometry (Å, º) for compounds 1 and 3  
          D-H···A       D-H       H···A       D···A     D-H···A 
   1 N(1)-H(1)···O(3) 0.86(4) 2.00(3) 2.668(4) 134(3) 
   3 N(1)-H(1)···O(3) 0.88 1.80 2.546(5) 141 
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Table 4 In vitro ID50 values (ng/ml) of test compounds 1-4 along with some reported organotin(IV) 
compounds against some standard drugs using as cell viability test in seven human tumour cell linesa 
 
Cell lines Test compoundb 
A498   EVSA-T  H226  IGROV M19 MELMCF-7WIDR 
 [Ph3SnL1H]n (1)  96 35 56 90 42 36 33 
 [Ph3SnL2H]n (2)  104 49 111 99 75 76 42 
 [Ph3SnL3H]n (3)  39 31 38 46 36 34 31 
 Ph2SnL2 (4)  987 278 849 199 409 452 405 
 [Ph3SnL4H]n.nCCl4 (5)c [49] 105 81 105 101 102 111 106 
 [Ph3SnL5H]n (6)c [49] 120 100 115 105 130 115 110 
 [Ph3SnL6H]n  (7)c [49] 113 96 108 106 112 110 109 
 {[nBu2Sn(2-OHC6H4C(CH3)=N(CH2)2COO)]2O}2 [47] 376 34 237 174 225 147 895 
DOX 90 8 199 60 16 10 11 
CDDP 2253 422 3269 169 558 699 967 
5-FU 143 475 340 297 442 750 225 
MTX 37 5 2287 7 23 18 <3.2 
ETO 1314 317 3934 580 505 2594 150 
TAX <3.2 <3.2 <3.2 <3.2 <3.2 <3.2 <3.2 
nBu2Sn(2-OC10H6C(H)=NCH2COO) [66] 170 35 190 75 90 75 480 
nBu2Sn(2-OC10H6C(H)=N(CH2)2COO) [66] 62 17 160 27 71 20 114 
nBu2Sn(2-OC(CH3)C(H)C(CH3)=NCHCH2CH(CH3)2COO [66] 130 120 200 130 70 60 420 
Ph2Sn(2-OC10H6C(H)=NCH2COO) [66] 230 70 350 120 530 170 490 
Ph2Sn(2-OC10H6C(H)=N(CH2)2COO) [66] 690 150 1100 480 620 600 1750 
DOX 55 13 180 150 21 25 18 
CDDP 1200 920 3160 230 780 1400 1550 
5-FU 340 720 5300 850 310 350 440 
MTX 16 26 70 20 18 15 7 
Carboplatin 18000 4500 25000 2400 5500 10500 3500 
Ph3SnR1d [27] 42 <3 39 19 42 17 17 
Ph3SnR2d [27] 65 <3 61 18 51 16 19 
Ph3SnR3d [27] <2 <2 <2 <2 <2 2.9 <2 
CDDP 2253 422 3269 169 558 699 967 
DOX 90 8 199 60 16 10 11 
aAbbreviation: DOX, doxorubicin; CDDP, cisplatin; 5-FU, 5-fluorouracil; MTX, methotrexate; ETO, etoposide and  
TAX, paclitaxel.  
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bStandard drug reference values are cited immediately after the test compounds under identical conditions. 
cReported triphenyltin(IV) compounds (5-7) have been included for comparison; see ref. 49: LH is a carboxylate 
residue where L4H, 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}phenylpropionate; L5H, 2-{[(E)-1-(2-
hydroxyphenyl)methylidene]amino}phenylpropionate; L6H, 2-{[(E)-1-(2-hydroxyphenyl)ethylidene]amino}- 
phenylpropionate.  
dReported triphenyltin(IV) compounds, R is a carboxylate residue where R1 = -terebate, R2 = -steroidcarboxylate, R3 = 
-benzocrowncarboxylate. 
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Fig. 1 Three repeats of the crystallographically and chemically unique unit in the polymeric [Ph3SnL1H]n  
chain structure of 1 (50% probability ellipsoids).  The H-atoms and one of the disordered conformations 
have been omitted for clarity. 
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Fig. 2 Three repeats of the crystallographically and chemically unique unit in the polymeric [Ph3SnL3H]n  
chain structure of 3 (50% probability ellipsoids).  The H-atoms and one of the disordered conformations 
have been omitted for clarity. 
 
 
